Key insights
- Personalis' annual shareholder meeting saw the election of directors, ratification of the auditor, and approval of executive compensation. While routine, the mixed Q1 earnings (revenue beat, EPS miss) mentioned in the article, combined with the stock's NASDAQ listing, suggests a slightly negative influence on US equities, primarily for PSNL itself. The EPS miss could raise concerns.
Personalis, Inc. (NASDAQ:PSNL) announced the results of its 2026 annual meeting of stockholders, held virtually on Tuesday. According to a press release statement based on an SEC filing, holders of 91,869,300 shares of common stock, representing 87.76% of the company’s outstanding shares as of the March 17, 2026 record date, were present in person or by proxy, constituting a quorum.
At the meeting, shareholders voted on three proposals:
-
Election of Directors: Olivia K. Bloom and Woodrow A. Myers, Jr., M.D., were elected as Class I directors to serve until the 2029 annual meeting. Bloom received 75,695,538 votes in favor and 317,559 votes withheld, while Myers received 68,240,509 votes in favor and 7,772,588 votes withheld. There were 15,856,203 broker non-votes for both nominees.
-
Ratification of Independent Auditor: Stockholders ratified the selection of BDO USA, P.C. as Personalis’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote was 91,586,300 in favor, 34,421 against, and 248,579 abstentions.
-
Advisory Vote on Executive Compensation: On a non-binding, advisory basis, shareholders approved the compensation of the company’s named executive officers. The results were 75,549,455 votes for, 384,918 against, and 78,724 abstentions, with 15,856,203 broker non-votes.
All proposals were approved as described in the company’s proxy statement filed with the SEC on April 2, 2026. Personalis is incorporated in Delaware and its common stock is traded on the Nasdaq Global Market under the symbol PSNL.
In other recent news, Personalis Inc. reported its first-quarter 2026 earnings, revealing a mixed financial performance. The company’s revenue exceeded expectations, reaching $15.47 million, which was 6.76% higher than the forecasted $14.49 million. However, the earnings per share (EPS) fell short of projections, coming in at -$0.29 compared to the anticipated -$0.27. The NeXT Personal MRD test showed significant growth, with a 258% year-over-year increase and a 26% quarter-over-quarter rise, and was ordered by over 1,000 oncologists in the first quarter. Additionally, the Centers for Medicare & Medicaid Services expanded coverage for the NeXT Personal test to include immunotherapy monitoring for late-stage solid tumor patients. BTIG adjusted its price target for Personalis to $11 from $13, maintaining a Buy rating, while Needham reiterated a Buy rating with a $12 price target, citing MRD growth. These developments highlight the company’s ongoing advancements and challenges in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.